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Obesity is a global problem which has reached epidemic proportions. Obesity is morbidly associated with 
metabolic syndrome, type-2 diabetes, cardiovascular disease and increased cancer risk. There is an alarming 
increase in the incidence of obesity in young children which puts them at a greater risk for developing 
diseases at a much earlier age. Obesity also imposes a heavy burden on the healthcare system. Lorcaserin, a 
novel anti-obesity drug, is a selective agonist to 5-HT2C receptors thereby reducing food intake and promoting 
weight loss.  Lorcaserin has 15-times and 100-times higher selectivity for the 5-HT2C receptor compared to the 
5-HT2A and 5-HT2B receptors, respectively. 
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Introduction 
Obesity is a global problem which has reached 
epidemic proportions. Obesity is morbidly associated 
with metabolic syndrome, type-2 diabetes, 
cardiovascular disease and increased cancer risk. There 
is an alarming increase in the incidence of obesity in 
young children which puts them at a greater risk for 
developing diseases at a much earlier age. Obesity also 
imposes a heavy burden on the healthcare system. 
Effective intervention for the treatment of 
obesity is bariatric surgery which involves invasive 
procedures and carries significant risks.1 Reducing 
calorie intake and leading an active lifestyle through 
regular exercise although is the best alternative but to 
achieve significant results takes  motivation and 
commitment over a long time course. Anti-obesity 
drugs are thus an important intervention as a short 
term treatment option to patients who are morbidly 
obese with complications and have restricted abilities 
to perform physical activity. Current anti-obesity drugs 
approved by United States Food and Drug 
Adminstration (USFDA) include phentermine, 
phentermine/topiramate (Qsymia) and lorcaserin.2,3 
 
Obesity and the serotonin system 
Serotonin has a pivotal role in the satiety and 
control of food intake. Various serotonin/5-
hydroxytryptamine (5-HT) receptors have been 
identified and of these, 5-HT2 subfamily is a target for 
many anti-obesity drugs. 5-HT2 receptor subfamily 
includes 5-HT2A, 5-HT2B   and 5-HT2C. 5-HT2C 
receptors are exclusively located in the central nervous 
system and are involved in the suppression of appetite. 
This vital role in appetite control makes 5-HT2C as a 
promising anti-obesity target. However, due to highly 
conserved amino acid sequence between the 5-HT2 
receptor subfamily, developing highly 5-HT2C selective 
drugs has been a challenging task. Non-selective 5-HT 
drugs have been shown to reduce body weight but had 
serious side effects owing to their activation of 5-HT2A 
and 5-HT2B receptors.4 
 
Lorcaserin – the new entrant   
Lorcaserin, a novel anti-obesity drug, was 
approved by FDA in June 20125, marketed by Arena 
Pharmaceuticals (San Diego, CA) under the trade 
name Belviq.  Chemically lorcaserin is [(1R)-8-chloro-
1-methyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine 
hydrochloride hemihydrate] and is a selective agonist 
to 5-HT2C receptors thereby reducing food intake and 
promoting weight loss.6,7  Lorcaserin has 15-times and 
100-times higher selectivity for the 5-HT2C receptor 
compared to the 5-HT2A and 5-HT2B receptors, 
respectively.8 
Lorcaserin is prescribed along with a low-
calorie diet and regular physical activity for obese 
patients who have Body Mass Index (BMI) of 30 
kg/m2 or overweight patients with BMI of 27-30 
kg/m2 and also have one of the obesity related 
conditions such as type-2 diabetes, high cholesterol or 
hypertension. 
 
Lorcaserin – the evidence   
Three clinical trials have been published so far 
evaluating the efficacy and safety of lorcaserin for 
weight loss in obese population: Behavioral 
modification and lorcaserin for overweight and obesity 
management (BLOOM), behavioral modification and 
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lorcaserin for overweight and obesity management in 
patients of diabetes mellitus type 2 (BLOOM DM) 
and behavioral modification and lorcaserin second 
study for obesity management (BLOSSOM).9-11 For 
the BLOOM and BLOSSOM trials, obese or 
overweight patients were randomized to receive either 
placebo or lorcaserin 10 mg twice daily for 52 weeks. 
BLOOM-DM had a similar study design but involved 
obese patients with type 2 diabetes. These 3 clinical 
trials demonstrated effective weight loss of ≥ 5-10% 
in lorcaserin treated obese patients compared to 
placebo and also demonstrated a positive outcome on 
glycated hemoglobin levels, fasting blood glucose, 
decrease in blood pressure and BMI along with weight 
loss in obese patients with type-2 diabetes. Meta-
analysis of pooled data from five clinical trials show 
that lorcaserin caused a modest reduction in the body 
weight but also caused significant side effects 
including headache, dizziness, nausea, upper 
respiratory tract infections and nasopharyngitis.12 
FDA-defined mitral regurgitation (valvulopathy) side 
effect also developed in 2.7 % of lorcaserin treated 
patients compared to 2.3% in placebo treated patients 
although statistically not significant.9 Other adverse 
side effects include depression and serotonin 
syndrome, when lorcaserin is used in combination 
with other serotonergic drugs such as serotonin-
norepinephrine reuptake inhibitors, monoamine 
oxidase inhibitors, antipsychotics to name a few. 
 
Concluding remarks  
Obesity is a growing health concern across the 
globe. FDA approval of lorcaserin is a significantly 
exciting step towards the treatment of obesity. 
However, large randomised clinical trials in 
comparison with other anti-obesity drugs are needed 
to address the benefit to risk ratio for the use of 
lorcaserin. 
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